原癌基因HER-2在乳腺癌中的研究进展

乳腺癌是造成女性死亡的主要恶性肿瘤之一,人类表皮生长因子受体2(HER-2)癌基因的扩增及其蛋白的过表达常提示肿瘤恶性程度高。研究表明,HER-2表达水平与肿瘤大小、病理类型、细胞分级及淋巴结转移情况无关,其过表达比率在各型乳腺癌中基本保持一致。作为乳腺癌的预后指标、治疗反应预测指标、治疗靶点和预测新辅助化疗疗效,HER-2研究成为国际肿瘤生物治疗的一项重大进展。

Proto-oncogene HER-2 in Breast Cancer Research

Breast cancer is one of the major causes of female cancer mortality while human epidermal growth factor receptor 2 （HER-2） oncogene amplification and protein over-expression often indicate a higher malignancy. And studies showed that the level of HER-2 expression was not correlated to tumor size, pathological type, grade and lymph node metastasis, whose ratio over-expression in all types of breast cancer remains constant. HER-2 as a prognostic indicator of breast cancer,treatment response,therapeutic targets and efficacy of neoadjuvant chemotherapy, the research on HER-2 has been a major advance in the biological therapy of cancer.